Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108
|
|
|
- Clemence Kelley
- 5 years ago
- Views:
Transcription
1 A Accuracy, 6, 7, 15, 46, 52, 53, 61, 75, 100, 143, 144, 149, 166, 176, 178 Acquired coagulation disorders, Acquired platelet disorders, ACT. See Activated clotting time (ACT) Activated clotting time (ACT), 27, 28, 30, 33 35, 37 39, 41, 42, 53, 137, 138, , 158, Activated protein C (APC), 20, 23, 27, 28, , 133, 167 ADAMTS-13, 111, 114, 115 Aggregometry, 40 41, 86, 99, 105, 162, 163, 179 AITP. See Autoimmune thrombocytopenic purpura (AITP) Alpha2 -antiplasmin, 79, 93 95, 114, 119 AMR. See Analytical measurement range (AMR) Analytical measurement range (AMR), 53 Anticardiolipin antibody assay, Anticoagulant, 13, 19 23, 25 27, 29 31, 33, 36, 41, 42, 55, 64, 70, 73, 78 80, 101, 117, , 125, , , , 184, Anticoagulant therapy, 70, , , Antiphospholipid antibody testing, 30, 130, 131 Antiplatelet drugs, , 173 Antithrombin (AT), 23, 24, 27, 33, 93, 94, , , , 133, , , 151, 152, , 167, 168 Antithrombin III. See Antithrombin (AT) Anti-Xa heparin assay, 27, 136, APC. See Activated protein C (APC) Apixaban, 30, 138, , 168, 196, 197 Argatroban, 137, , 167, 168 AT. See Antithrombin (AT) Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108 B Bernard-Soulier syndrome, 79, 84, 87, 88 Bethesda assay, 95, 96 Bivalirudin, 137, 157, 167, 168 Bleeding time (BT), 39, 70, 76 77, 85, 92, 105, 163 C CABG. See Coronary artery bypass grafting (CABG) Calibration, 34, 47 48, 53, 94, 96, , 168 CAP. See College of American Pathologists (CAP) Capillary, 23 25, 35, 36, 40 Cardiopulmonary bypass (CPB), 102, 107, , 146, 152, 168, 184, 193 CBC. See Complete blood count (CBC) Clauss method, 75 CLIA-88. See Clinical Laboratory Improvement Amendments (CLIA-88) Clinical and Laboratory Standards Institute, 15, 19, 21, 22, 28, 49, 142 Clinical Laboratory Improvement Amendments (CLIA-88), 3, 4, 6, 8, 10, 15 Clopidogrel, 40, 41, 106, 107, 162, 164, 165, 173, Coagulation assay, 23, 26, 35, 83, 90, 123, 131, 132, 183, 184, 186, 187, 189, , 197, 198 disorders, 83, 84, 92 93, specimens, collection of, Springer International Publishing Switzerland 2015 S.T. Bennett et al., Laboratory Hemostasis: A Practical Guide for Pathologists, DOI /
2 202 College of American Pathologists (CAP), 1, 4, 6, 8, 10, 15, 33, 76, 103, 119, 121, 122, 124, 126, 127, 129, 142, 154, 175, 178 Complete blood count (CBC), 41, 69 70, 163 Contamination, specimen, 24, 29, 193 Coronary artery bypass grafting (CABG), 106, 153 CPB. See Cardiopulmonary bypass (CPB) Crossover study, 23, 47, 56, 57, 65 Cryoprecipitate, 38, 190, , 198 CYP2C9, CYP2C19, 173, 174, D Dabigatran, 30, 137, , 167, 168, 196, 197 D-dimer, 24, 27, 34, 47, 62, 75 76, 78 80, , 130, 167, 183, 186, 192, 194, 196 Deep venous thrombosis (DVT), 122, 139, 146, 149, 154 Detection methods, 29, 34 35, 100, 107 DIC. See Disseminated intravascular coagulation (DIC) Dilute Russell viper venom time (DRVVT), 132, 167 Dilutional coagulopathy, Discard tube. See Pilot tube Disseminated intravascular coagulation (DIC), 29, 71 73, 75, 76, 78 80, 95, 111, 112, 114, 115, 128, 146, 186, 192, Drotrecogin alfa. See activated protein C DRVVT. See Dilute Russell s Viper Venom time (DRVVT) DVT. See Deep venous thrombosis (DVT) E ECMO. See Extracorporeal membrane oxygenation (ECMO) Education, 2 5, 9, 14, 15 Electro-mechanical detection, 34 Extracorporeal membrane oxygenation (ECMO), 37, 136, 146 F Factor activity, 141, 167 Factor inhibitor screen. See Mixing studies, PT and PTT Factor V Leiden, 27, 30, 83, , 133 Factor VIII, 27, 34, 72, 73, 77, 84, 88 92, 94 97, 111, 114, 119, 120, , 127, 129, 132, 148, 151, 167, 190 Factor VIII antibodies. See Inhibitor assays Factor IX, 27, 72, 73, 84, 92, 94, 97, 119, 120, 139, 146, 167 Factor XIII, 70, 72, 75, 83, 84, 93 94, 112, 113, 122, 164, 190 FDP. See Fibrin/fibrinogen degradation products (FDP) FFP. See Fresh frozen plasma (FFP) Fibrin/fibrinogen degradation products (FDP), 35, 74, 75, 78, 79, Fibrinogen, 24, 27, 33, 35, 38, 39, 41, 47, 62, 70, 72 76, 78 80, 84, 85, 93 95, , 119, 140, 148, , 167, , , , 198 Fibrinolysis, 39, 78, 95, 111, 112, 114, 115, Fondaparinux, 137, 147, 152, , 159, 167, 168 Fresh frozen plasma (FFP), 36, 38, 136, 184, , 196 FSP. See Fibrin/fibrinogen split products (FSP) G β 2 Glycoprotein-1, 130, 131, 133 H Hematocrit, 20 23, 29, 41, 106, 135, 138, 196 Hemolysis, 24, 25, 29, 30, 35, 100 Hemostasis screening assays, Heparan. See Unfractionated heparan Heparan sulfate, 118 Heparin contamination, 24, 29 Heparin-induced thrombocytopenia (HIT), 71, 79, , 108, 149, 150, , 187 HIT. See Heparin induced thrombocytopenia (HIT) HLA. See Human leukocyte antigens (HLA) Homocysteine, 123, , 133 Homocysteinemia, , 123, 133 Human leukocyte antigens (HLA) antibody, 101, 102, 187, 188 antibody tests, 102 I Icterus, 29 Immune-mediated thrombocytopenia (ITP), 71, , 155 Inhibitor assays, INR. See International normalized ratio (INR) Instrumentation, 11, 33 42, 105, 152
3 Interferences, 29, 34 36, 41, 52, 53, 75, 100, 101, 126, 136 International normalized ratio (INR), 20, 24, 28, 30, 33, 35 37, 41, 42, 53, 58 61, 63, 64, 71, 136, 138, , 150, , 166, 168, , 183, 184, 189, 190 International Sensitivity (ISI), 20, 35, 36, 58 61, , 145, 166, 184 ISI. See International Sensitivity (ISI) ISO 15189, 16 ITP. See Immune-mediated thrombocytopenia (ITP) Myocardial infarction (MI), 119, 135, 139, 146, 149, 154, 161 N NAIT. See Neonatal alloimmune thrombocytopenia (NAIT) Neonatal alloimmune thrombocytopenia (NAIT), 101, 102, 104 New oral anticoagulants (NOACs), 30, NOACs. See New oral anticoagulants (NOACs) 203 L LA. See Lupus anticoagulant (LA) Laboratory director, role and responsibilities, 1 16, 45 Laboratory information system (LIS), 48 50, 52, Laboratory thrombosis testing, 117, Light transmission aggregometry (LTA), 40, 86, 105, 162, 179 Lipemia, 29, 35 LIS. See Laboratory information system (LIS) LMWH. See Low molecular weight heparin (LMWH) Low molecular weight heparin (LMWH), 62, 74, 146, 147, 151, 152, , 159, 160, 166, 168 LTA. See Light transmission aggregometry (LTA) Lupus anticoagulant (LA), 23, 26, 27, 33, 36, 55, 64, 73, 78 80, 125, , 145, 151, 152, 159 M Mean normal prothrombin time (MNPT), 58 61, 140, 141, 143, 145, 166, 168 Mechanical detection, 34, 35, 42 Method comparison, 15, 56 61, 142 Methylene tetrahydrofolate reductase (MTHFR), 121, 122, 126 MI. See Myocardial infarction (MI) Mixing studies, PT and PTT, 80, 112, 114, 183, 185, MNPT. See Mean normal prothrombin time (MNPT) MTHFR. See Methylene tetrahydrofolate reductase (MTHFR) Multiplate, 39, 40 Myeloproliferative disorders, 79, 99, 105, 123, 129, 130 O Optical detection, 100 Order of draw, 25, 31 P PaGIA. See Particle gel immunoassay (PaGIA) Partial thromboplastin time (PTT), 20, 24, 26, 28, 29, 33 35, 37 39, 41, 51, 53 56, 62 64, 69, 72 75, 77, 78, 80, 90, 92 94, 112, 114, 115, 125, 127, 128, 132, , , , , , Particle gel immunoassay (PaGIA), 103 PE. See Pulmonary embolism (PE) Personnel, 2 7, 11 14, 30, 46, 47, 49, 63, 64, 70 PFA. See Platelet function analyzers (PFA) PFA -100, 26, 39 41, 85, 92, 106, 163, 179 Pharmacogenetic, Photo-optical detection, 34, 42 Pilot tube, 24 Plasma calibrants, 144, 160, 166 Plasmin, 75, 76, 95, 113, 114, 119, 195 Platelet activating factor, 85, 87, 104 aggregation, 26, 39 41, 77 79, 85 89, 92, 96, 99, 102, 149, 167, 176, 177 antibody testing, counting methods, function testing, 86, 99, , 162, 165, 168, 179 transfusion, 88, 101, 102, , 193, 197, 198 Platelet function analyzers (PFA), 27, 28, 39, 41, 42, 92, 99, 107 Platelet-poor plasma, 26, 31, 86, 132 Platelet-rich plasma (PRP), 26, 39, 40, 85, 86, 88, 96, 99, 105, 163 Plateletworks, 39, 41, 163, 179
4 204 Point-of-care testing, 30, 152, 153, 176 Porcine factor VIII, 96 Post-transfusion purpura (PTP), 101, 104 Prasugrel, 107, 162, Pre-analytic considerations, Precision, 6, 38, 49, 52, 53, 75, 100, 144, 168 Protein C assay, 127 Protein S assay, Prothrombin gene mutation, 117, 119, 121, 123, 126, 127, 133 Prothrombin time (PT), 20, 23, 24, 26, 28 30, 33 39, 41, 42, 53, 54, 56, 58, 62, 63, 69 75, 77, 78, 80, 92 94, 112, 114, 115, 125, 128, 132, 138, , 145, 150, 159, 161, , 175, 176, 178, , PRP. See Platelet-rich plasma (PRP) PT. See Prothrombin time (PT) PTP. See Post-transfusion purpura (PTP) PTT. See Partial thromboplastin time (PTT) Pulmonary embolism (PE), 139, 146, 149, 154 Q QC. See Quality control (QC) Qualitative platelet disorders, 79, 83 85, 87, 88, 91, 92 Quality control (QC), 2, 6, 13, 14, 36, 47 50, 53, 66 Quality management, 1 3, 8, 13 14, 16 R Reference intervals, 13, 20, 47, 50 52, 55, 57, 63 66, 76, 80, 93, 94, 97, 127, 133, 186 Reference method, 36, 38, , 108, , 168 Ristocetin, 28, 77, 86 89, 92, 94, 96 Rivaroxaban, 30, 138, , 167, 168, 196, 197 ROTEM, 38 S Safety, 1 3, 6, 12, 13, 15, 16, 36, 62, 173, 191 Sample collection. See Specimen collection Sensitivity, 20, 35, 39 41, 52, 54 56, 58, 64, 65, 70, 72, 76, 93, , 130, , 145, 149, 150, 160, 161, , 184, 189 Serotonin release assay (SRA), , 150 Sonoclot, 38, 39 Specimen collection, 2, 22, 24, 25, 29 31, 51, 145, 153, 164 SRA. See Serotonin release assay (SRA) Stability reagent, 53 specimen, 26, 27, 54, 151 T TEG. See Thromboelastography (TEG ) Testing for acquired platelet disorders, TFPI. See Tissue factor pathway inhibitor (TFPI) Thienopyridines, 41, 106, 107, 162, 176, 177 Thrombin generation time, 85, 113, 149, 153, 195 time (TT), 23, 26, 28, 33, 34, 53, 56, 74, 75, 78, 79, 114, 137, 138, , 167 Thrombocytopenia, 41, 70, 71, 79, 84, 87, , 107, 112, 115, 129, 130, 149, 150, 155, 156, , 193 Thromboelastography (TEG ), 26, 28, 30, 38, 39, 105, 106, 164, Thrombomodulin (TM), Thrombosis testing, 117, , Thrombotic thrombocytopenic purpura (TTP), 71, 100, , 129, 130, 187, 191 Ticlopidine, 40, 162 Tissue factor pathway inhibitor (TFPI), 148 Tissue-plasminogen activator (TPA), 113, TM. See Thrombomodulin (TM) TPA. See Tissue-plasminogen activator (TPA) Transfusion, 36, 38, 41, 42, 88, , 104, 107, 108, TT. See Thrombin, time (TT) TTP. See Thrombotic thrombocytopenic purpura (TTP) U UFH. See Unfractionated heparin (UFH) Ultra-high-molecular-weight multimers of von Willebrand factor (UHMWM- vwf), 111, 115 Unfractionated heparin (UFH), 37, 56, 62, 72, 73, 108, , 159, 166, 168, 186 Uremia, 79, V VAD. See Vascular access devices (VAD)
5 Validation of hemostasis assays, analyzers, and reagents, Vascular access devices (VAD), 23 25, 29, 30 Venous thromboembolism (VTE), 75, 76, 80, , 156, 158, 160 VerifyNow, 26 28, 30, 39, 41, 161, 179 Viscoelastic, 35, 38 39, 41, 42 Vitamin K deficiency, 70, 78, 80, , 115, 128 VKORC1, von Willebrand factor (vwf), 23, 28, 34, 40, 41, 47, 77, 83, 85, 87 92, 94, 96, 111, 114, 148, 167, multimeric analysis, 91, 96 von Willebrand s disease (vwd), 77, 79, 80, 83, 84, 87 92, 96, 97 VTE. See Venous thromboembolism (VTE) vwf. See von Willebrand factor (vwf) W Waived PT/INR instruments, Warfarin, 24, 35, 36, 58, 63, 70, 78, 80, 112, 125, 129, , 150, 159, 160, 166, 167, , 184, 190, 197 Whole blood aggregometry, 105
Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117
www.cap.org Coagulation Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Serviced (CMS). Coagulation Limited CGL, CGDF Analyte CGL CGDF New
Coagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
Hypercoagulation. CP Conference 11/14/2006
Hypercoagulation CP Conference 11/14/2006 Overview Hypercoagulation: poorly understood phenomena No definite cause is identified in > 40% of cases Three major factors in thrombus formation (Rudolf Virchow,
Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
S1865 Coagulation Testing: How Do We Get the Best Results?
S1865 Coagulation Testing: How Do We Get the Best Results? John D. Olson, MD, PhD, FCAP Kristi J. Smock, MD, FCAP S1865 Coagulation Testing: How do we get the best results? John D. Olson, MD, PhD University
General Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis
1 Nadanotes.com 2 Nadanotes.com 3 Nadanotes.com Platelet type bleeding: (vwd) - Petechiae, purpura, ecchymoses, bruising - Menorrhagia, hematuria, occult GI bleed - Gingival bleeding, epistaxis Clotting
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis
2 Thomas G. DeLoughery
Tests of Hemostasis and Thrombosis 2 Thomas G. DeLoughery A routine laboratory test once well-established is often slavishly adhered to, with little further thought about how it originated, why it is done
Laboratory Monitoring of Anticoagulation
Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.
UW Medicine Alternative Monitoring for Antithrombotic Agents
Tags: monitoring alternative monitoring SUMMARY OF ANTICOAGULATION LAB TESTS AT UWMedicine Description Order Code Specimen Collection Availability Turn-Around Time Anti Xa Based Tests antixa for heparin
Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:
Special Coagulation - APC Resistance DiaPharma Group, Inc. Customer Service: 1.800.526.5224 Technical Support:1.800.447.3846 www.diapharma.com 1 Review of Hemostasis Overview Pathways of coagulation, anticoagulation,
Managing the Risks Associated with Anticoagulant Therapy. Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde
Managing the Risks Associated with Anticoagulant Therapy Steve McGlynn Specialist Principal Pharmacist (Cardiology) NHS Greater Glasgow and Clyde Background Identified as high risk medicines Wide range
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
Phoenix, AZ Laboratory - Test Menu
Laboratory - Menu Laboratory ame CPT Code Specimen Requirement Methodology Assay Schedule Reference Range Available ing (/) 320908 E90237 Abnormal PT/aPTT Reflexive Profile (aptt, Prothrombin Time/IR,
Category Storage Shelf Life Additional Criteria
CE Update [blood banking/transfusion medicine] Blood Components for Hemostasis Jun Teruya, MD, DSc, and Glenn Ramsey, MD From the Department of Pathology, Northwestern University Medical School, Chicago.
Phoenix, Arizona, Laboratory Test Menu
Menu Phoenix, Arizona, Laboratory ame CPT Code Specimen Requirement Methodology Assay Schedule Reference Range Available ing 320908 Abnormal PT/aPTT Reflexive Profile (aptt, Prothrombin Time/IR, Thrombin
Phoenix, AZ Laboratory - Test Menu
- Menu Laboratory umber ame CPT Code Specimen Requirement Methodology Assay Schedule Reference Range Available (/) 320908 E90237 Abnormal PT/aPTT Reflexive Profile (aptt, Prothrombin Time/IR, Thrombin
Principles of Coagulation Testing. Andy Nguyen, MD 8/4/2010
Principles of Coagulation Testing Andy Nguyen, MD 8/4/2010 FSP and D-Dimer FDP vs. D-DIMER Fibrin is formed as the end result of coagulation cascade activation Fibrinolysis causes cleavage of fibrinogen,
TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued
TSOAC Case Study 1 An otherwise healthy 56-year-old man presents to the emergency department with left leg pain and swelling for the last 3 days. Compression ultrasonography confirms left common femoral
Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
Haemostasis Reagents product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch Product # ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Product name
Coagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications
Thromboelastography (TEG): Basics & Clinical Applications Paula J. Santrach MD Associate Professor, Laboratory Medicine Mayo Clinic Rochester, MN Disclosures Relevant financial relationships NONE Off label
DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic
DOAC s and Implications on Laboratory Results Kandice Kottke-Marchant, MD, PhD Cleveland Clinic Anticoagulants Heparin Low Molecular Weight Heparins enoxaparin, fragmin Heparin pentasaccharide - fondaparinux
ECAT FOUNDATION. External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis
ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis SURVEY MANUAL 2016 ECAT FOUNDATION Postal address Visiting address ECAT Foundation ECAT
Laboratory Monitoring of Unfractionated Heparin Therapy
1 PATHOLOGY & LABORATORY MEDICINE December, 2015 Laboratory Monitoring of Unfractionated Heparin Therapy On November 18, 2015, the Thrombosis and Hemostasis Laboratory transitioned from the aptt to the
Clumsy Coagulation Communication
Clumsy Coagulation Communication Let s Blame the Lab! Lab Clinician Communication Barriers and opportunities Where are the errors made? How do we enhance patient experience? George A Fritsma MS, MLS, Your
Antithrombosis Management for Pediatric VAD and Beyond
Antithrombosis Management for Pediatric VAD and Beyond Christina VanderPluym M.D. Director of Ventricular Assist Device and Cardiac Antithrombosis Program Boston Children s Hospital, USA Disclosures I
Information about and Monitoring of Anticoagulant Therapy
Warfarin (Coumadin) Indications for warfarin Treatment of arterial and venous thrombosis to prevent clot propagation Prevention of thromboembolic disease in thrombophilia, atrial fibrillation, mechanical
Basic coagulation applications and case studies
Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases
Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016
Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be
Heparin-Induced Thrombocytopenia and New Anticoagulants
Heparin-Induced Thrombocytopenia and New Anticoagulants September 2004 Elizabeth M. Van Cott, MD Massachusetts General Hospital Boston MA College of American Pathologists 2004. Materials are used with
Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS
Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1 Learning Objectives Explain the concept of thrombophilia Recognize
Pharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
The Coagulation Workup In The Office Setting
CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Primary & Secondary Hemostasis Disorders http://.columbia.edu/itc/hs/medical/selective/advclinicalpathology/2004/lecture/lab%20diagnosis%20of%20bleeding%20disorders.ppt
Marcia L. Zucker, Ph.D. ZIVD LLC
Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 Picture courtesy of Helena Laboratories 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia
Platelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
LABORATORY APPROCH TO THE BLEEDING PATIENT
Anne Winkler, MD Emory University School of Medicine, Atlanta Georgia Assistant Professor, Pathology & Laboratory Medicine Medical Director, Transfusion Service, Grady Health System Assistant Director,
Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis
Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium
Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
Blood Product Utilization
Who gets what & when Why not to give blood? Volume Expander For specific number (except as related to procedures) To patients with religious objections to blood transfusions Blood given only when necessary
Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.
Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated
Evaluation of Unexplained Prolonged APTT &/or PT Review & Update
Evaluation of Unexplained Prolonged APTT &/or PT Review & Update 12-2016 William L. Nichols, M.D. Special Coagulation Lab, Coagulation Clinic & Hemophilia Center 2016 MFMER slide-1 Prolonged APTT &/or
Celluvative. Cellular Therapies Redefined. A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow.
Cellular Therapies Redefined A portfolio of products and services brought to you by: Saving lives today. Improving life tomorrow. cell u va tive / sel-yoo-vā-tiv/ noun 1. a partnership between BloodCenter
Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO
Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining
Customer Service. For further product information, technical advice, prices or to place an order contact. Phone:
Customer Service For further product information, technical advice, prices or to place an order contact Phone: + 43 1 86373-0 Fax: + 43 1 86373-44 Sales: sales@technoclone.com Product Support: products@technoclone.com
ECAT FOUNDATION. External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis
ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis PROGRAMME MANUAL 2018 ECAT FOUNDATION Postal address Visiting address ECAT Foundation
New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D.
New Insights into the Diagnosis & Management of Venous Thromboembolism (VTE) Michael Miller, M.D. Professor of Cardiovascular Medicine University of Maryland School of Medicine Copyright A.P. Wheeler 2009
DOS Updates. M Pneumoniae DNA PCR QL Discontinued send out test to Mayo. Replaced by Mycoplasma pneumo PCR QL to ARUP, effective December3.
IU Health Pathology Laboratory News Bulletin December 11, 2013 DOS Updates Citrate Platelet Count New hematology test. This test is used to evaluate patients suspected of EDTA mediated platelet clumping.
CE Update. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis
Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis Emmanuel J. Favaloro, PhD, MAIMS, FFSc (RCPA), 1 Dorothy M. (Adcock) Funk, MD, 2 Giuseppe Lippi, MD 3 ( 1
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
Preanalytical note's for Blood coagulation tests
Preanalytical note's for Blood coagulation tests importance The use of modern laboratory instrumentation with high levels of test reliability and appropriate quality assurance measures will lead to very
Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015
+ Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates
Lina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof
2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have
Automated Coagulation Analyser product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Automated Coagulation
Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1
Review of Bleeding Disorders Case 1 Robert I. Handin, MD Professor of Medicine, Harvard Medical School Hematology Division Brigham & Women s Hospital 20 year college student is home on spring break and
QUALITY PROGRAMME MANUAL 2014
QUALITY PROGRAMME MANUAL 2014 Release: 021213PM CONTENT THE ECAT FOUNDATION... 3 1. GENERAL INFORMATION... 4 1.1 ECAT OFFICE INFORMATION... 4 1.2 LEGAL ENTITY... 4 1.3 SUBCONTRACTED ACTIVITIES... 5 1.4
ECAT FOUNDATION. External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis
ECAT FOUNDATION External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis PROGRAMME MANUAL 2017 ECAT FOUNDATION Postal address Visiting address ECAT Foundation
Heparin Induced Thrombocytopenia
Screen Heparin Induced Thrombocytopenia This course has been awarded one (1) contact hour. This course expires on September 30, 2018. Copyright 2007 by RN.com. All Rights Reserved. Reproduction and distribution
Update on the Direct Oral Anticoagulants (DOACs)
Update on the Direct Oral Anticoagulants (DOACs) J. Randle Adair DO, PhD Internal Medicine New Mexico Cancer Center & Co-Chair, Anticoagulation Subcommittee Presbyterian Healthcare Services (PHS) Attending,
Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation
Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Coagulation Cascade XII XIIa XI HMWK/Prekallikrein XIa VII Injury IX X IXa VIII Xa X TF TF/VIIa Prothrombin
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014
Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.
Anticoagulation in VTE The Haematologist s Perspective. Dr. M.D. Maina FRCP Edin.
Anticoagulation in VTE The Haematologist s Perspective Dr. M.D. Maina FRCP Edin. Disclosures None The coagulation process that leads to haemostasis involves a complex set of reactions involving approximately
Hemostasis/Thrombosis IV
Hemostasis/Thrombosis IV Antithrombotic Therapy Antithrombotic Therapy Mainstay of battle against thromboembolic disease Hot area of new drug research Cannot inhibit clot formation without increased risk
Upon completion of the Clinical Hematology rotation, the MLS student will be able to:
Clinical Performance Objectives in Clinical Hematology Department of Medical and Research Technology University of Maryland School of Medicine Spring 2015 Upon completion of the Clinical Hematology rotation,
With Stago, discover an outstanding Routine range
In Haemostasis, There s routine... and then there s Routine With Stago, discover an outstanding Routine range An optimal Routine range for guaranteed satisfaction 1 Comprehensive range Stago s extensive
Antithrombotic Therapies: Parenteral Agents
Antithrombotic Therapies: Parenteral Agents Christine A. Sorkness, Pharm.D. Professor of Pharmacy & Medicine (CHS) UW School of Pharmacy Clinical Pharmacist, Anticoagulation Clinic, Wm S. Middleton VA
Vesalius SCALpel : Coagulation. Coagulation
Vesalius SCALpel : Coagulation Coagulation Clotting tests injury attracts platelets chemoattractants: platelet derived growth factor (PDGF), transforming growth factor beta (TGF beta) platelets release
General News. Product Notes. Instrument Notice HELENA SALES FORCE TO: FROM: SUBJECT: HELENA POINT OF CARE ROUND-UP/US DOMESTIC DATE: 9/1/2009
TO: FROM: SUBJECT: HELENA SALES FORCE DATE: 9/1/2009 General News HELENA POINT OF CARE ROUND-UP/US DOMESTIC We have concluded a very large meeting with the AACC in Chicago. The leads have been processed
Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1
Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1 Donna D. Castellone, MS, MT (ASCP) SH Clinical Project Manager Hematology and Hemostasis Siemens Healthcare Diagnostics Disclosures
2015 Catalogue Coagulation
2015 Catalogue Coagulation 1 CONTENTS Reagents TriniCLOT TM Routine Reagents PT 4 aptt 4 Fibrinogen 5 Thrombin Time 5 Factor Deficient Plasmas 5 Solutions 5 TriniLIA TM D-Dimer TriniLIA TM D-Dimer 6 TriniCLOT
ANEMIA. Oral iron. IV iron gluconate (order set #233)
PREVENTION ANEMIA Oral iron IV iron gluconate (order set #233) TRANSEXAMIC ACID Efficacy of IV TXA in Reducing Blood Loss After Elective C-section: Prospective, Randomized, Double-blind, Placebo Controlled
Pharmacotherapy Management in Patients with Extracorporeal Membrane Oxygenation
Pharmacotherapy Management in Patients with Extracorporeal Membrane Oxygenation Ayesha Ather, PharmD, BCPS College of Pharmacy, Adjunct Assistant Professor University of Kentucky Faculty Disclosure I have
Hematology Emergencies: Problems with Platelets
Hematology Emergencies: Problems with Platelets Christian Cable, MD, FACP Associate Professor of Medicine Division of Hematology & Oncology Texas A&M HSC College of Medicine Scott & White Healthcare Fundamentals
Managing Coagulation Abnormalities Linda Liu, M.D.
Managing Coagulation Abnormalities Professor UCSF Dept of Anesthesia UC SF 1 Difficult Task Coagulation Abnormalities 30 minutes Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban UC SF 2 UC
Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.
Excel with Confidence Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc. 2015 All rights reserved. General Lab Challenges Test Volume Financial Performance Accuracy Reliability
Heparin-induced thrombocytopenia a diagnostic and therapeutic challenge
Heparin-induced thrombocytopenia a diagnostic and therapeutic challenge Christopher M Ward Northern Blood Research Centre Royal North Shore Hospital Royal North ShoreHospital ISTH Bangkok November 2017
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Haemostasis & Thrombosis Department St. Thomas Hospital Westminster Bridge Road London SE1 7EH United Kingdom Contact: Beverly Earl Tel: +44 (0) 20 7188 0084 Fax: +44 (0) 20 7188 2726 E-Mail: beverley.earl@viapath.co.uk
Coagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation
Diagnosing Haemostasis PRODUCT CATALOG
Diagnosing Haemostasis PRODUCT CATALOG CONTENTS MTI COAGULATION ANALYZER MT1C- Single Channel Semi Automated Coagulation Analyzer MT4C- Four Channel Semi Automated Coagulation Analyzer Bera - New Generation
Marcia L. Zucker, Ph.D. ZIVD LLC
Marcia L. Zucker, Ph.D. ZIVD LLC 1 Explain why ACTs from different systems are not the same Develop a plan for switching from one ACT system to another Describe why ACT and aptt are not interchangeable
SSAR-SGAR Jahreskongress SAOA Meeting November 7, 2013
SSAR-SGAR Jahreskongress SAOA Meeting November 7, 2013 How can we evaluate clotting? PD Dr. med. Michael Ganter Institute of Anesthesiology and Pain Medicine Conflict of interest statement In the past
Marcia L. Zucker, Ph.D. ZIVD LLC
Marcia L. Zucker, Ph.D. ZIVD LLC 1 Monitoring hemostasis Bleeding Clotting 2 3 Extrinsic Pathway Monitor with ACT / aptt WARFARIN Monitor with PT Common Pathway X II Xa LMWH & DXaI IIa (thrombin) Hirudin
QUALITY PROGRAMME MANUAL 2013
QUALITY PROGRAMME MANUAL 2013 Release: 070113PM CONTENT THE... 3 1. GENERAL INFORMATION... 4 1.1 ECAT OFFICE INFORMATION... 4 1.2 LEGAL ENTITY... 4 1.3 SUBCONTRACTED ACTIVITIES... 5 1.4 MISSION... 5 1.5
Bleeding Emergencies. Gregory W. Hendey, MD, FACEP Professor of Clinical Emergency Medicine UCSF Fresno
Bleeding Emergencies Gregory W. Hendey, MD, FACEP Professor of Clinical Emergency Medicine UCSF Fresno Objectives To discuss indications and agents used for reversal of coagulopathy To apply those principles
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
Quality in the Coagulation Laboratory: Trending Standardization and EQA
Quality in the Coagulation Laboratory: Trending Standardization and EQA Robert C Gosselin, CLS Hemophilia Treatment Center UC Davis Health System, Sacramento, CA rcgosselin@outlook.com NASCOLA is a nonprofit
Clinical Use of Plasma for Transfusion. Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School
Clinical Use of Plasma for Transfusion Irma Szymanski, MD Professor of Pathology, Emerita University of Massachusetts Medical School PLASMA PRODUCTS FOR TRANSFUSION Fresh Frozen Plasma (FFP) Thawed Plasma
DOACs: When and how to measure their anticoagulant effect
DOACs: When and how to measure their anticoagulant effect Stavroula Tsiara MD, PhD, FRCP Associate Professor of Internal Medicine University of Ioannina, Greece NOACs NOACs, TSOACs, DOACs (ISTH) Target
Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays
Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays Richard A. Marlar Ph.D. University of Oklahoma THSNA Meeting- Chicago, IL April 14-16, 2016 DISCLOSURE Richard A. Marlar, PhD
Coagulation: The Ins and Outs. Sheila K. Coffman BSMT (ASCP)
Coagulation: The Ins and Outs Sheila K. Coffman BSMT (ASCP) Coagulation Testing: What is it? Monitoring hemostasis Bleeding Clotting Coagulation Testing Monitoring therapy Heparin Monitor with ACT / aptt
REVIEW- CLASSIC VS MODERN
HEMOSTASIS 2 REVIEW- CLASSIC VS MODERN ANTICOAGULANT THERAPY Injectable- heparin and heparin derivatives Unfractioned heparin Low molecular weight heparins Oral- antivitamin K inhibitors Coumadins- most